After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco for the industry's biggest investor event of the year. Monday, we'll be ...
ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase ...
PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical ...
SAN FRANCISCO—After a year of significant disruption at Novo Nordisk, the company's R&D chief has told Fierce Biotech that the deal-hungry Danish pharma is largely sticking to its metabolic roots as ...
Ionis Pharmaceuticals’ launch of Tryngolza (olezarsen) is off to a flying start as a treatment for familial chylomicronemia syndrome (FCS). With the California drugmaker preparing to roll Tryngolza ...
Winter Olympics organisers have admitted that parts of the opening ceremony were pre-recorded after fevered debate about ...
Recent significant rises in the use of ketamine by young people, and in the harms it can cause – in particular in relation to bladder damage, dependence, and drug-related deaths - have led to growing ...
The combination of GENEROUS for Medicaid, Globe for Medicare Part B and Guard for Medicare Part D will heavily impact the US drug market. President Trump’s rhetoric has been that other countries ...
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, ...
Benchmarks surge up to 5% intraday after India-US trade deal; export, pharma, auto stocks rally as rupee gains and FII return hopes rise.
The death of Isaias Castillo IV is New Jersey’s first pediatric flu death of the 2025-2026 season, according to state health officials Kimberlee Speakman is a digital writer at PEOPLE. She has been ...